DSIJ Mindshare

Max India is set to enter businesses with adjacencies to current group businesses of life insurance, real estate, senior care and hospitality. The company is in the midst of selling 51 per cent stake in Health Insurance JV Max Bupa, to a leading private equity firm True North which is expected to be completed in the next six months.

Cipla with its subsidiary, Cipla USA has received approval for ANDA for Ambrisentan Tablets from the US drug regulator. The shares of the company were trading in red in the morning session.

Leading private banker Yes Bank's shares tumbled on Tuesday as the bank posted a loss of Rs. 1,507 crore for the March quarter. In the early morning session on Tuesday, the stock was down by more than 25 per cent at Rs. 177.90 per share.

Glenmark announced the launch of its patent-protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.

Overall volumes in futures & options currently stand at 1.10 crore contracts with a turnover of Rs. 7,32,837.82 crore.